Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 16 2014
Print

Financial Report: Alkermes



Published January 31, 2013
Alkermes

3Q Revenues: $135.9 million (+8%)

3Q Earnings: $16.3 million (loss of $14.8 million 3Q11)

YTD Revenues: $412.1 million (+59%)

YTD Earnings: $22.0 million (loss of $50.3 million YTD11)

Comments: Net sales of Vivitrol were $15.9 million, up 50%. Manufacturing and royalty revenues (M&R) were $118.3 million in the quarter, up 5%, and $364 million YTD, up 67%. Risperdal Consta and Invega Sustenna/Xeplion M&R revenues were $52.5 million in the quarter, up 10%. M&R revenues from Ampyra/Fampyra were $18.4 million, up 74%, and royalty revenues from Bydureon were $5.3 million, compared to $0.3 million in 3Q12. Other M&R revenues, which includes contract manufacturing operations, were $25.4 million in the quarter. R&D revenue was $1.7 million, down 24%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On